TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16819583

Group type: EXPERIMENTAL
Intervention: Fentanyl infusion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Response Entropy (RE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Response Entropy activation
Number of subjects: 40

Group type: COMPARATOR
Intervention: BIS
Number of subjects: 40
Study: 12767369

Group type: COMPARATOR
Intervention: IFN‐alpha monotherapy
Number of subjects: 3065

Group type: EXPERIMENTAL
Intervention: Combination of surgery and immunotherapy
Number of subjects: 3065

Group type: COMPARATOR
Intervention: Combination of IFN‐alpha and Il‐2
Number of subjects: 3065

Group type: COMPARATOR
Intervention: Combination of IFN‐alpha, Il‐2 and 5‐fluorouracil (5‐FU)
Number of subjects: 3065
Study: 10493320

Group type: EXPERIMENTAL
Intervention: Flunisolide (1000 microg twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Budesonide (1000 microg twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Beclomethasone (1000 microg twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Triamcinolone (1000 microg twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluticasone (1000 microg twice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8087114

Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation with positive end-expiratory pressure (CPPV)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Pressure-controlled inverse ratio ventilation (PCIRV)
Number of subjects: 8
Study: 2681551

Group type: EXPERIMENTAL
Intervention: Stage-shift cancer screening model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data from a completed breast cancer screening RCT
Number of subjects: 0
Study: 972558

Group type: EXPERIMENTAL
Intervention: Drug profile provided to half of the study population for a full year.
Number of subjects: 1632

Group type: COMPARATOR
Intervention: No drug profile provided (control group).
Number of subjects: 1632
Study: 31927220

Group type: EXPERIMENTAL
Intervention: Mindfulness (self-reported at baseline)
Number of subjects: 53
Study: 30588705

Group type: EXPERIMENTAL
Intervention: Active rTMS intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 20
Study: 28988170

Group type: EXPERIMENTAL
Intervention: HuCare Quality Improvement Strategy (HQIS)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 720
Study: 26475731

Group type: EXPERIMENTAL
Intervention: Frequency-domain optical coherence tomography (FD-OCT) assessment of morphometric stent parameters
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Qualitative evaluation of strut coverage using FD-OCT
Number of subjects: 10
Study: 23980354

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at acupoints combined general anesthesia (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Electroacupuncture at non-acupoints combined general anesthesia (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: General anesthesia (Group C)
Number of subjects: 90
Study: 21464262

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) for 20 minutes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (quiet relaxation for 20 minutes)
Number of subjects: 25
Study: 19095726

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8901
Study: 16923410

Group type: EXPERIMENTAL
Intervention: Detection of atrial high-rate episodes (AHRE) with pacemaker telemetry
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Overdrive atrial pacing
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Noninvasive testing capabilities of the pacemaker
Number of subjects: 400
Study: 15144494

Group type: EXPERIMENTAL
Intervention: Generalizing knowledge based on goals and topics (younger children)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Clustering based on principles related to disciplines (older children)
Number of subjects: 256
Study: 10996348

Group type: EXPERIMENTAL
Intervention: Apo E4/4 (n=36)
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Apo E3/4 (n=209)
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Apo E3/3 (n=412)
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Apo E2/3 (n=66)
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Apo E4(+) (apo E3/4 and 4/4 combined)
Number of subjects: 1062
Study: 9024260

Group type: EXPERIMENTAL
Intervention: GHRH infusion (1 microgram/kg bolus at 0900 h, then 1 microgram/kg/h for 21 h)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: GHRP-2 infusion (1 microgram/kg bolus at 0900 h, then 1 microgram/kg/h for 21 h)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: GHRH plus GHRP-2 infusion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 26
Study: 7898866

Group type: EXPERIMENTAL
Intervention: Early-treatment group (5-FU injections started 2.4 +/- 0.6 days postoperatively)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Delayed-treatment group (5-FU injections started 12.6 +/- 5.4 days postoperatively)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Early-treatment group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Delayed-treatment group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 3310297

Group type: EXPERIMENTAL
Intervention: CMF (cytoxan, methotrexate, and 5-fluorouracil) for 1 year
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: CMF with tamoxifen for 1 year
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: CMF with or without bacillus Calmette-Guérin (BCG) for 1 year
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Patients with first local-regional recurrence
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Patients with any recurrence
Number of subjects: 311
Study: 31844922

Group type: EXPERIMENTAL
Intervention: EPVL 3 days after RIRS
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: EPVL 7 days after RIRS
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: EPVL 14 days after RIRS
Number of subjects: 176

Group type: COMPARATOR
Intervention: No EPVL after RIRS (Control Group)
Number of subjects: 176
Study: 30064491

Group type: EXPERIMENTAL
Intervention: Adalimumab (80 mg then 40 mg 2 weeks later)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8
Study: 28854937

Group type: EXPERIMENTAL
Intervention: Intervention a + b (workshop and intensive training)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intervention a + b + c (workshop, intensive training, and action learning sets)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9
Study: 25952495

Group type: EXPERIMENTAL
Intervention: Medication-taking consistency
Number of subjects: 190
Study: 24030939

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1000-3000 IU/d)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 21406000

Group type: EXPERIMENTAL
Intervention: Schwarz appliances
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 19014494

Group type: EXPERIMENTAL
Intervention: XM02 (5 microg/kg/day for at least 5 days and a maximum of 14 days)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Neupogen (5 microg/kg/day for at least 5 days and a maximum of 14 days)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study: 17147795

Group type: EXPERIMENTAL
Intervention: Iron fortified instant noodles
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 425

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Iron fortification
Number of subjects: 425
Study: 14614165

Group type: EXPERIMENTAL
Intervention: 10 mg CTLA4Ig per kilogram
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: 2 mg CTLA4Ig per kilogram
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study: 11374857

Group type: EXPERIMENTAL
Intervention: Immediate-release niacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (Niaspan)
Number of subjects: 0
Study: 8780292

Group type: EXPERIMENTAL
Intervention: Instructional video review of VT1 prior to VT2
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no instructional review)
Number of subjects: 29
Study: 1385567

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg intravenous doses, two doses: one before anesthesia induction and one 8 hours later)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (two doses of placebo vehicle: one before anesthesia induction and one 8 hours later)
Number of subjects: 50
Study: 6881960

Group type: EXPERIMENTAL
Intervention: Naloxone 0.8 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naloxone 1.6 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31591063

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus erlotinib (150 mg/day erlotinib, 10 mg/kg ramucirumab every 2 weeks)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo plus erlotinib (150 mg/day erlotinib)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus erlotinib
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo plus erlotinib
Number of subjects: 449
Study: 29118087

Group type: EXPERIMENTAL
Intervention: Overweight (BMI 25.0-29.9 kg/m2)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Obese (BMI ≥30 kg/m2)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Normal weight (BMI 18.5-24.9 kg/m2; reference group)
Number of subjects: 441
Study: 27356991

Group type: EXPERIMENTAL
Intervention: My Own Health Report (MOHR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 18
Study: 25204098

Group type: EXPERIMENTAL
Intervention: Two-year alcohol prevention program (Program Domowych Detektywów and Fantastyczne Mozliwości)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 802
Study: 21451504

Group type: EXPERIMENTAL
Intervention: PF‐4878691 (3, 6, and 9 mg doses, twice a week for 2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF‐4878691 (9 mg dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF‐4878691
Number of subjects: 0
Study: 19653753

Group type: EXPERIMENTAL
Intervention: Correct grip with correct goal location
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body-related objects (e.g., cup) with movement toward the subject's body
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: World-related objects (e.g., pincers) with movement in the opposite direction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual semantics retrieval (Experiment 4)
Number of subjects: 0
Study: 16965983

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (enoxaparin, 4000 IU/d, n = 56 hypertensive patients)
Number of subjects: 94

Group type: COMPARATOR
Intervention: No treatment (n = 38 hypertensive women)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Healthy controls (n = 30)
Number of subjects: 94
Study: 14976884

Group type: EXPERIMENTAL
Intervention: Modified Zhizhu pill (ZZP) 100 ml, twice daily, orally taken half an hour before meal
Number of subjects: 63

Group type: COMPARATOR
Intervention: Ranitidine 0.15 g, twice daily and Cisapride 10 mg, three times a day, orally taken before meal
Number of subjects: 63
Study: 11122219

Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9382344

Group type: EXPERIMENTAL
Intervention: Medical advice (Group 1)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (Group 2)
Number of subjects: 353

Group type: COMPARATOR
Intervention: No treatment (Group 3)
Number of subjects: 353
Study: 8407393

Group type: EXPERIMENTAL
Intervention: IUdR 96 hr infusion schedule
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: IUdR 48 hr infusion schedule
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: IUdR 24 hr infusion schedule
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 79
Study: 2426940

Group type: EXPERIMENTAL
Intervention: 1% permethrin cream rinse
Number of subjects: 573

Group type: COMPARATOR
Intervention: 1% lindane shampoo
Number of subjects: 573
Study: 4582638

Group type: EXPERIMENTAL
Intervention: Experimental infection with Mycoplasma pneumoniae
Number of subjects: 67
Study: 30658657

Group type: EXPERIMENTAL
Intervention: mHealth cancer pain assessment intervention delivered via the QStream online platform over four weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-listed control group (not receiving the mHealth intervention).
Number of subjects: 0
Study: 27682748

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with epinephrine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline with epinephrine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Preoperative phenazopyridine
Number of subjects: 90

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 90
Study: 26063688

Group type: EXPERIMENTAL
Intervention: CPAP with best supportive care (BSC)
Number of subjects: 278

Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 278

Group type: COMPARATOR
Intervention: BSC
Number of subjects: 278
Study: 24622369

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 899

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 899
Study: 22092641

Group type: EXPERIMENTAL
Intervention: Moraxella bovis autogenous vaccine
Number of subjects: 369

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study: 19747937

Group type: EXPERIMENTAL
Intervention: Weight-Wise intervention (n=72)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Wait-listed control group (n=71)
Number of subjects: 143
Study: 16701090

Group type: EXPERIMENTAL
Intervention: Age greater than 70 years
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Extended resection
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Main pancreatic duct diameter of 3 mm or less
Number of subjects: 300
Study: 14978607

Group type: EXPERIMENTAL
Intervention: Exercise and scheduled-toileting intervention (provided every two hours, four times per day, five days a week for 32 weeks)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Exercise and scheduled-toileting intervention
Number of subjects: 89
Study: 11408369

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice daily)
Number of subjects: 12
Study: 9200633

Group type: EXPERIMENTAL
Intervention: Implementation of the Ottawa ankle rules during the intervention period.
Number of subjects: 4210

Group type: COMPARATOR
Intervention: Control group (no intervention during the intervention period).
Number of subjects: 4210

Group type: EXPERIMENTAL
Intervention: Postintervention period with posters alone to sustain the effect.
Number of subjects: 4210
Study: 8290859

Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg daily for 28 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2975285

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 200 micrograms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 80 micrograms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (both dosages)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30571402

Group type: EXPERIMENTAL
Intervention: Genetically determined serum iron
Number of subjects: 48972

Group type: EXPERIMENTAL
Intervention: Genetically determined ferritin
Number of subjects: 48972

Group type: EXPERIMENTAL
Intervention: Genetically determined transferrin saturation
Number of subjects: 48972

Group type: EXPERIMENTAL
Intervention: Genetically determined transferrin
Number of subjects: 48972
Study: 26492971

Group type: EXPERIMENTAL
Intervention: Interdisciplinary program (geriatric consultation, in-hospital rehabilitation, discharge planning, rehabilitation at home for 3 months)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual care (in-hospital rehabilitation and occasional discharge planning)
Number of subjects: 153
Study: 24230461

Group type: EXPERIMENTAL
Intervention: Positive psychology exercises
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Gratitude exercises
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Personal strengths exercises
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Other positive psychology exercises
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study: 22107114

Group type: EXPERIMENTAL
Intervention: Neonatal deaths due to prematurity/low birth-weight
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Neonatal deaths due to intrapartum-related causes (birth asphyxia)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Neonatal deaths due to infections
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Neonatal deaths due to congenital malformation
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Neonatal deaths occurring within the first 24 hours after delivery
Number of subjects: 238
Study: 20444662

Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: glimepiride+metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: metformin
Number of subjects: 0
Study: 18721198

Group type: EXPERIMENTAL
Intervention: Single gram of intramuscular ceftriaxone
Number of subjects: 400

Group type: COMPARATOR
Intervention: 3-day course of oral ciprofloxacin
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Single oral 500 mg of ciprofloxacin
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 400
Study: 17013573

Group type: EXPERIMENTAL
Intervention: TAX/RT (paclitaxel 90 mg/m² or docetaxel 35 mg/m²)
Number of subjects: 36

Group type: COMPARATOR
Intervention: TAX/CIS/RT (paclitaxel 135 mg/m² d1 and cisplatin 20 mg/m² d1-5 q28)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TAX/RT
Number of subjects: 36

Group type: COMPARATOR
Intervention: TAX/CIS/RT
Number of subjects: 36
Study: 15226460

Group type: EXPERIMENTAL
Intervention: NCEP Step 2 high‐fish diet (n = 11, 26% of energy as fat, 4.5% as saturated fat, and 15 mg cholesterol/MJ)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: NCEP Step 2 low‐fish diet (n = 11, 26% of energy as fat, 4.0% as saturated fat, and 11 mg cholesterol/MJ)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: NCEP Step 2 high‐fish diet
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: NCEP Step 2 low‐fish diet
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Neither diet
Number of subjects: 22
Study: 10949017

Group type: EXPERIMENTAL
Intervention: Active dilator (A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Placebo (P)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 15
Study: 14685384

Group type: EXPERIMENTAL
Intervention: High-fat oral supplement (Group I)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard diet without supplement (Control Group II)
Number of subjects: 14
Study: 8457050

Group type: COMPARATOR
Intervention: 30 ml 2% lidocaine, followed by 10 ml every 45 min (Control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 15 ml of 3% chloroprocaine (containing EDTA), plus 5 ml every 45 min
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 30 ml of 3% chloroprocaine plus 10 ml every 45 min
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 30 ml of 3% chloroprocaine (containing metabisulfite as the preservative but no EDTA) plus 10 ml every 45 min
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 30 ml of 3% chloroprocaine with the pH adjusted to 7.3, plus 10 ml every 45 min
Number of subjects: 100
Study: 3836297

Group type: EXPERIMENTAL
Intervention: Labetalol (100, 200, 400, 600 mg BID)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 or 50 mg BID)
Number of subjects: 35
Study: 31685227

Group type: EXPERIMENTAL
Intervention: Higher serum ferritin values
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum ferritin of 17 μg/L
Number of subjects: 0
Study: 30224032

Group type: EXPERIMENTAL
Intervention: Rise of 1st follow-up sodium (Na) at day 3 (n=43)
Number of subjects: 89

Group type: COMPARATOR
Intervention: No rise in 1st follow-up sodium (Na) at day 3 (n=46)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Cox regression analysis for rise in 1st follow-up Na
Number of subjects: 89
Study: 26974582

Group type: EXPERIMENTAL
Intervention: Self-monitoring during Phase 1 (6-month intervention)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Self-monitoring during Phase 2 (12-month extended care)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Self-monitoring during Phase 2
Number of subjects: 167
Study: 25240564

Group type: EXPERIMENTAL
Intervention: Ozone-augmented percutaneous discectomy (OPLD)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Caudal epidural
Number of subjects: 147
Study: 22781573

Group type: EXPERIMENTAL
Intervention: Infective group (patients with fungal infections)
Number of subjects: 697
Study: 20074265

Group type: EXPERIMENTAL
Intervention: Subtotal abdominal hysterectomy (SH)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Total abdominal hysterectomy (TH)
Number of subjects: 200
Study: 17299465

Group type: EXPERIMENTAL
Intervention: High MUFA diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-fat control diet
Number of subjects: 18
Study: 16153351

Group type: EXPERIMENTAL
Intervention: Aggressive care
Number of subjects: 466

Group type: COMPARATOR
Intervention: Symptomatic care
Number of subjects: 466
Study: 12847531

Group type: EXPERIMENTAL
Intervention: 2-day antibiotic therapy (AT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 4-day antibiotic therapy (AT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Neutrophil values (NV), C-reactive protein (CRP), procalcitonin (PCT)
Number of subjects: 26